Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.
Rossi C, Tosolini M, Gravelle P, Pericart S, Kanoun S, Evrard S, Gilhodes J, Franchini DM, Amara N, Syrykh C, Bories P, Oberic L, Ysebaert L, Martin L, Ramla S, Robert P, Tabouret-Viaud C, Casasnovas RO, Fournié JJ, Bezombes C, Laurent C. Rossi C, et al. Among authors: bories p. Haematologica. 2022 Jan 1;107(1):221-230. doi: 10.3324/haematol.2020.263194. Haematologica. 2022. PMID: 33327711 Free PMC article.
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.
Bertoli S, Bories P, Béné MC, Daliphard S, Lioure B, Pigneux A, Vey N, Delaunay J, Leymarie V, Luquet I, Blanchet O, Cornillet-Lefebvre P, Hunault M, Bouscary D, Fegueux N, Guardiola P, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Récher C; Groupe Ouest-Est d’Etude des Leucémies Aiguës et Autres Maladies du Sang (GOELAMS). Bertoli S, et al. Among authors: bories p. Haematologica. 2014 Jan;99(1):46-53. doi: 10.3324/haematol.2013.091819. Epub 2013 Aug 23. Haematologica. 2014. PMID: 23975179 Free PMC article. Clinical Trial.
Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Evrard SM, Péricart S, Grand D, Amara N, Escudié F, Gilhodes J, Bories P, Traverse-Glehen A, Dubois R, Brousset P, Parrens M, Laurent C. Evrard SM, et al. Among authors: bories p. Haematologica. 2019 Apr;104(4):e154-e157. doi: 10.3324/haematol.2018.198572. Epub 2018 Oct 11. Haematologica. 2019. PMID: 30309852 Free PMC article. No abstract available.
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: bories p. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
[Chimeric antigen receptor T cells].
Bories P, Ysebaert L. Bories P, et al. Bull Cancer. 2021 Oct;108(10S):S55-S64. doi: 10.1016/j.bulcan.2021.08.003. Bull Cancer. 2021. PMID: 34920808 Review. French.
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. Bachy E, et al. Among authors: bories p. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22. Nat Med. 2022. PMID: 36138152 Free PMC article.
CD34+CD38-CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents.
Vergez F, Nicolau-Travers ML, Bertoli S, Rieu JB, Tavitian S, Bories P, Luquet I, Mas V, Largeaud L, Sarry A, Huguet F, Delabesse E, Bérard E, Récher C. Vergez F, et al. Among authors: bories p. Cancers (Basel). 2020 May 6;12(5):1174. doi: 10.3390/cancers12051174. Cancers (Basel). 2020. PMID: 32384744 Free PMC article.
Dactinomycin in acute myeloid leukemia with NPM1 mutations.
Beziat G, Tavitian S, Bertoli S, Huguet F, Largeaud L, Luquet I, Vergez F, Rieu JB, Bories P, Delabesse E, Récher C. Beziat G, et al. Among authors: bories p. Eur J Haematol. 2020 Sep;105(3):302-307. doi: 10.1111/ejh.13438. Epub 2020 May 25. Eur J Haematol. 2020. PMID: 32452083
197 results